ANRO insider trading

Healthcare

Alto Neuroscience, Inc.: insider trade history from SEC Form 4 filings.

Total Form 4 trades
32
Last 90 days
7
Buys / sells
28% / 9%
Market cap
$555.62M

About Alto Neuroscience, Inc.

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD. The company was incorporated in 2019 and is headquartered in Mountain View, California.

Company website: www.altoneuroscience.com

ANRO insider activity at a glance

FilingIQ tracks 32 insider transactions for ANRO in filings since Feb 7, 2024. The most recent transaction is dated Oct 2, 2026.

Across the full history, 9 open-market purchases and 3 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

How FilingIQ classifies each line, and the seven facts it shows on every open-market purchase and sale, are documented on the methodology page.

Latest ANRO Form 4 filings

Most recent disclosures. Sign up to filter by transaction code, insider role or dollar value.

Other Healthcare tickers with recent insider activity

Most active insiders at ANRO

By number of Form 4 lines in the last 180 days.

Frequently asked

How many insider trades does FilingIQ track for ANRO?
FilingIQ tracks 32 Form 4 insider transactions for ANRO (Alto Neuroscience, Inc.), covering filings from Feb 7, 2024 onwards. 7 of those are dated within the last 90 days.
Are ANRO insiders net buyers or net sellers?
Across the full Form 4 history for ANRO, 9 transactions (28%) were open-market purchases and 3 (9%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does ANRO insider data come from?
Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ links every filing to the insider's SEC CIK, marks plan trades, tax withholding, option exercises, gifts, derivatives and amendments, and shows each open-market purchase and sale with the same fixed facts. It does not rate the stock.
What sector is ANRO in?
Alto Neuroscience, Inc. (ANRO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $555.62M.

Methodology & sources

Every ANRO insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). How lines are classified and which facts FilingIQ adds is documented on the methodology page; the people behind it are on the team page. Not investment advice; see disclaimer.